CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    32,000

Stocks News & Analysis

stocks

ASX healthcare stocks shrug off new tariff threat

Trump’s announcement could directly affect CSL, but we expect the firm to respond accordingly.
personal-finance

Why I was probably too quick to dismiss passive investing

Weighing up different approaches to investing is not a case of one being right and the other being wrong.
stocks

12 picks for an income portfolio - Q2 2025 update

One year in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,928.9950.530.64%
DAX 4024,579.6130.050.12%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,959.5892.561.04%
HKSE24,028.37136.050.57%
NASDAQ20,611.34192.870.94%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers